As with vaccines, treatments are being reviewed at a rapid pace. This section will be updated frequently.
Treatment Trial Data
- Eli Lilly’s monoclonal antibody LY-CoV555, in an interim analysis of phase 2 clinical trial data from non-hospitalized patients, showed a reduction in viral load and some decrease in symptoms compared to placebo with the 2800mg dose. (October 28, 2020)
- Regeneron’s phase 2/3 trial results for their monoclonal antibody cocktail REGN-CoV2 indicates a more rapid reduction in viral load and medical visits compared to placebo. (October 29, 2020)
- Regeneron and Eli Lilly have stopped the trial of their monoclonal antibodies in hospitalized patients due to a safety concern and lack of effectiveness. (October 30, 2020)
- The effectiveness of convalescent plasma for COVID-19, although approved by the FDA, has been called into question based on the latest study. (BMJ, October 22, 2020)
Emergency Use Authorization (EUA) Approvals
- Casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years of age or older weighing at least 40 kilograms (about 88 pounds) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. (November 21, 2020)
- The combination of baricitinib with remdesivir for hospitalized patients with COVID-19. (November 19, 2020)
- Eli Lilly’s monoclonal antibody bamlanivimab for non-hospitalized COVID-19 patients 12 years of age or older with mild to moderate COVID-19 and at high risk for severe disease. In 12-17 year olds, asthma or other chronic respiratory disease that requires daily treatment is specified as a high risk marker. (November 9, 2020)
- CMS has announced that Medicare will cover these infusions without cost sharing and anticipate giving the antibody product to healthcare providers at no cost and paying for infusion. Later, Medicare anticipates setting the payment rate in the same way it set the payment rates for COVID-19 vaccines.